Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial.

Gastrointestinale Tumore – interdisziplinäre Diskussion neuer Daten

“…In der MRC-COIN-Studie [51] wurde die durchgehend bis zur Progression applizierte Chemotherapie mit einer Stop-and-Go-Variante (12 Wochen Induktionsphase, dann Pause bis zum Progress) verglichen. Letztere zeigte ein geringfügig schlechteres OS (14,3 Monate vs. 15,6 Monate; HR 1,087), war aber deutlich besser verträglich (nur 5% Oxaliplatin-assoziierte Polyneuropathien des Grades 3 vs. 18% unter der kontinuierlichen Gabe) [68]. In der 3-armigen NORDIC-VII-Studie [52] wurde im Stop-and-Go-Arm Cetuximab kontinuierlich bis zur Progression gegeben, während die Chemotherapie nach 16 Wochen gestoppt und erst im Falle der Progression wiederaufgenommen wurde.…”

Recent developments and future perspectives in the systemic treatment of metastatic colorectal cancer

“…Recently, data from the Phase III MRC COIN study comparing continuous XELOX or FOLFOX with intermittent treatment (initial therapy for 12 weeks and continuation of treatment upon progression) revealed a small reduction in OS of 1.3 months in the experimental arm. However, this was balanced by less toxicity and a median 10 weeks less time on treatment [13] and clearly supports the use of intermittent treatment strategies in the palliative setting.…”

The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation

“…Twelve of these studies did not meet the inclusion criteria as they assessed a different population group from that specified in the research protocol 111,[123][124][125][126][127][128][129][130][131] or were conference abstracts. 132,133 Also the study by Lorenz and colleagues 134 was found irretrievable by the time of completion of the current report. From the updated searches, 12 titles and abstracts were screened and no study was found to meet the inclusion criteria.…”